治疗癫痫新药-呲仑帕奈

Epilepsy is one of the most common neurological disorders. At present, there are more than 50 million epilepsy patients in the world; according to statistics, there are about 9 million epilepsy patients in China, and about 400,000 new epilepsy patients are added every year. On October 15, Eisai announced that the National Medical Products Administration has approved its new anti-epileptic drug perampanel (generic name: Perampanel, English name: FYCOMPA, Chinese trade name: Wei Ketai) for the additional treatment of adults and children aged 12 years and above with partial seizures (with or without secondary generalized seizures).

Perampanel is a first-in-class anti-epileptic tablet developed by Tsukuba Research Center and is taken orally once daily. The drug is a highly selective, non-competitive AMPA receptor antagonist that can prevent and treat epilepsy by targeting and inhibiting the glutamate activity of postsynaptic membrane AMPA receptors and reducing the over-excitation of nerves associated with epileptic seizures. Perampanel was first approved by the FDA in 2012 for the adjuvant treatment of partial seizures in epilepsy patients over 12 years old, regardless of whether the patient has secondary generalized seizures. This is the first anti-epileptic drug approved by the FDA with this mechanism of action.

Perampanel not only has a unique mechanism, but is also based on sufficient evidence. The 2018 American Academy of Neurology (AAN) and American Epilepsy Society (AES) guidelines recommend perampanel as a Class A drug for the combined treatment of refractory epilepsy in adults. This is mainly based on a large amount of high-quality evidence-based evidence.

It was approved to be launched in China on September 29, 2019, and has now been included in the national medical insurance to provide everyone with government discounts to reduce the financial burden. But even after medical insurance, the price of parampanel remains high, prohibiting many families. However, according to Medical Companion Brigade, parampanel is more suitable for long-term use by patients and more cost-effective than other versions. Since the exchange rate has been in a state of fluctuation for a long time, the price fluctuates with the exchange rate and is not static. For more information about Parapanel, please contact Medical Companion Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: